Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Delayed Nasdaq
Other stock markets
 12:12:44 2024-05-03 pm EDT 		5-day change 1st Jan Change
2.16 USD +0.70% Intraday chart for Barinthus Biotherapeutics plc -13.60% -41.46%
May. 01 Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024 CI
Apr. 18 Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vaccitech Shares Rise After Alliance Global Partners Begins Coverage With Buy Rating
MT
Alliance Global Partners Initiates Coverage on Vaccitech with Buy Rating, $12 Price Target
MT
Morgan Stanley Downgrades Vaccitech to Equal Weight From Overweight, Cuts Price Target to $3.25 From $14
MT
Morgan Stanley Adjusts Price Target on Vaccitech to $14 From $15, Maintains Overweight Rating
MT
Morgan Stanley Adjusts Price Target on Vaccitech to $15 From $16, Maintains Overweight Rating
MT
HC Wainwright Adjusts Price Target on Vaccitech to $15 From $20, Maintains Buy Rating
MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities
MT
Morgan Stanley Adjusts Price Target on Vaccitech to $16 From $19, Maintains Overweight Rating
MT
HC Wainwright Adjusts Vaccitech's Price Target to $20 From $22, Keeps Buy Rating
MT
Morgan Stanley Trims Vaccitech's Price Target to $19 From $20, Maintains Overweight Rating
MT
HC Wainwright Adjusts Price Target on Vaccitech to $23 From $25, Maintains Buy Rating
MT
VACCITECH : Barclays Initiates Coverage on Vaccitech With Overweight Rating, $23 Price Target
MT
VACCITECH : William Blair Initiates Coverage on Vaccitech With Outperform Rating
MT
VACCITECH : Morgan Stanley Starts Vaccitech at Overweight With $22 Price Target
MT
VACCITECH : Jefferies Starts Vaccitech at Buy With $28 Price Target
MT
VACCITECH : HC Wainwright Starts Vaccitech at Buy With $25 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. News Barinthus Biotherapeutics plc
  5. Analyst Reco.